Interrogating tumor metabolism and tumor microenvironments using molecular positron emission tomography imaging. Theranostic approaches to improve therapeutics.

摘要: Positron emission tomography (PET) is a noninvasive molecular imaging technology that becoming increasingly important for the measurement of physiologic, biochemical, and pharmacological functions at cellular levels in patients with cancer. Formation, development, aggressiveness tumor involve number pathways, including intrinsic cell mutations extrinsic interaction between cells microenvironment. Currently, evaluation these processes mainly through biopsy, which invasive limited to site biopsy. Ongoing research on specific target molecules its microenvironment PET showing great potential. To date, use diagnosing local recurrence metastatic sites various cancers treatment response based [18F]fluorodeoxyglucose ([18F]FDG), measures glucose metabolism. However, [18F]FDG not target-specific tracer does give enough insight into biology and/or vulnerability potential treatments. Hence, there an increasing need development selective biologic radiotracers will yield biochemical information allow imaging. The possibility cancer-associated targets provide opportunity diagnosis therapy monitoring (theranostics) thus personalized medicine. This article focus review non-[18F]FDG tracers their preclinical clinical applications.